Gilead Sciences, Inc. (GILD) Announces Executive Promotions

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the promotion of Andrew Cheng, MD, PhD to Executive Vice President, HIV Therapeutics and Development Operations, and Taiyin Yang, PhD, to the role of Executive Vice President, Pharmaceutical Development and Manufacturing. Dr. Cheng and Dr. Yang will both join Gilead's senior leadership committee.

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.